Obstructive Sleep Apnea is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Obstructive Sleep Apnea have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Obstructive Sleep Apnea compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Obstructive Sleep Apnea overview
Obstructive sleep apnea (OSA) is defined by episodes of either complete collapse or partial collapse of the airway during sleep, accompanied by a reduction in oxygen saturation or awakening from sleep. This disruption leads to fragmented and nonrestorative sleep. The implications of OSA extend to various aspects of health, including cardiovascular well-being, mental health, overall quality of life, and safety while driving fatigue and reduced productivity. Moreover, OSA poses risks to driving safety, as drowsiness from poor sleep can lead to accidents, emphasizing the need for early diagnosis and effective management.
For a complete picture of PTSR and LoA scores for drugs in Obstructive Sleep Apnea, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
